Mangostin.

Alpha-mangostin is practically insoluble in water, so an unformulated powder taken on an empty stomach presents very little dissolved material to the intestinal wall. A medium chain triglyceride vehicle keeps it in solution through the stomach and feeds it into mixed micelles in the duodenum. This is standard behaviour for lipophilic plant actives rather than something measured for this molecule specifically.

Phosphatidylcholine forms mixed micelles with bile salts and dietary lipid, and lipophilic actives partition into that phase. For a xanthone with negligible aqueous solubility, that partitioning is the route into the enterocyte. The mechanism is established for lipophilic compounds generally. The size of the gain for alpha-mangostin has not been quantified in human work.

Alpha-tocopherol is the main chain-breaking antioxidant inside membranes and lipoproteins. Alpha-mangostin is also lipophilic and partitions into the same compartment, so the two are not simply duplicating each other in different phases. Animal and laboratory work on alpha-mangostin reports changes in oxidative markers such as malondialdehyde, which are markers of lipid peroxidation and not clinical outcomes.

Ascorbate sits at the water side of the membrane interface and reduces the tocopheroxyl radical back to tocopherol, sustaining the lipid-phase defence rather than replacing it. A lipophilic xanthone taken alongside participates in the same interfacial chemistry. The recycling relationship is textbook. What it does to any health endpoint in a person taking mangostin is a separate question with no answer yet.

Reduced glutathione is the cell's main thiol buffer, and studies of alpha-mangostin in animals and cell systems commonly report tissue glutathione as an outcome measure. That makes glutathione a marker in this literature, not a demonstrated partner. Oral glutathione is also poorly absorbed intact, so co-supplementation is a different proposition from what those studies measured.

N-acetylcysteine is deacetylated to cysteine, the rate-limiting substrate for glutamate-cysteine ligase and therefore for glutathione synthesis. That is settled biochemistry and does not depend on mangostin. Where alpha-mangostin studies report tissue glutathione, supplying the precursor addresses the same pool from the substrate side. No study has combined the two.

Quercetin and prenylated xanthones are both substrates for UDP-glucuronosyltransferases and sulfotransferases in the gut wall and liver. Co-ingestion at high amounts can slow the conjugation of whichever compound is present in excess, raising circulating levels of the other. That cuts both ways and is a pharmacokinetic interaction rather than a benefit, so the direction here is competition for shared enzymes.

Curcuminoids and alpha-mangostin share very low aqueous solubility, extensive first-pass conjugation and low oral bioavailability in the unformulated state. They are frequently combined in the same lipid or cyclodextrin systems because one formulation solves the problem for both. The pairing is formulation logic, and it does not by itself imply a combined biological effect.